Journal article
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, CL Scott, W Meier, R Shapira-Frommer, T Safra, D Matei, A Fielding, S Spencer, B Dougherty, M Orr, D Hodgson, JC Barrett, U Matulonis
Obstetrical and Gynecological Survey | LIPPINCOTT WILLIAMS & WILKINS | Published : 2015
Abstract
ABSTRACT Greater than 20% of cases of high-grade serous ovarian cancer are due to germline or somatically acquired BRCA mutations. Poly(ADP-ribose) polymerase inhibitors have been investigated as treatment for a number of tumors, including those due to BRCA mutations. One potent oral poly(ADP-ribose) polymerase inhibitor, olaparib, has shown antitumor activity in patients with both BRCA and sporadic high-grade serous ovarian cancer. A previous randomized, double-blind, placebo-controlled phase 2 study showed that twice-daily maintenance treatment with oral olaparib in patients with platinum-sensitive recurrent serous ovarian cancer significantly improved progression-free survival (PFS). Subg..
View full abstract